Fulvestrant ('Faslodex'): Clinical experience from the Compassionate Use Programme

Cancer Treatment Reviews

Volumn 31, Issue SUPPL. 2, 2005, Pages

  Steger, Guenther G ^a   Gips, Maya ^b   Simon, Sergio D ^c   Lluch, Ana ^d   Vinholes, Jefferson ^e   Kaufman, Bella ^f   Wardley, Andrew ^g   Mauriac, Louis ^h  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e Santa Casa Complexo Hospitalar   (Brazil)

^f SHEBA MEDICAL CENTER   (Israel)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h INSTITUT BERGONIÉ   (France)

Author keywords

'Faslodex'; Aromatase inhibitors; Breast cancer; Fulvestrant; Hormone dependent neoplasms; Metastatic; Oestradiol antagonists; Selective oestrogen modulators; Tamoxifen

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; GESTAGEN; LETROZOLE; PROGESTERONE RECEPTOR; RECEPTOR BLOCKING AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TAMOXIFEN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; BREAST CANCER; CANCER CENTER; CANCER HORMONE THERAPY; CLINICAL TRIAL; DATA ANALYSIS; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EXPERIENCE; HOT FLUSH; HUMAN; INJECTION SITE REACTION; NAUSEA; PROTEIN EXPRESSION; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; PALLIATIVE CARE; POSTMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 27144494936     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.08.009     Document Type: Article

References (14)

1. A.E. Wakeling Use of pure antioestrogens to elucidate the mode of action of oestrogens Biochem Pharmacol 49 1995 1545-1549
2. A.E. Wakeling Similarities and distinctions in the mode of action of different classes of antioestrogens Endocr Relat Cancer 7 2000 17-28
3. A.E. Wakeling M. Dukes J. Bowler A potent specific pure antiestrogen with clinical potential Cancer Res 51 1991 3867-3873
4. A. Howell J.F.R. Robertson J. Quaresma Albano et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 2002 3396-3403
5. C.K. Osborne J. Pippen S.E. Jones et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial J Clin Oncol 20 2002 3386-3395
6. J.F. Robertson C.K. Osborne A. Howell et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women - a prospective combined analysis of two multicenter trials Cancer 98 2003 229-238
7. I. Vergote J.F.R. Robertson U. Kleeberg G. Burton C.K. Osborne L. Mauriac Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy Breast Cancer Res Treat 79 2003 207-211
8. J.F.R. Robertson A. Howell V.A. Gorbunova T. Watanabe T. Pienkowski M.R. Lichinitser Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant Breast Cancer Res Treat 92 2005 169-174
9. L. Perey R. Paridaens F. Nolé Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer (ABC) progressing after treatment with tamoxifen and aromatase inhibitors: Update of a phase II SAKK trial Breast Cancer Res Treat 88 Suppl. 1 2004 S236 [abstr 6048]
10. Ingle JN, Rowland KM, Suman VJ, et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: A phase II trial of the North Central Cancer Treatment Group. Poster presentation at the San Antonio breast cancer symposium, 8-11 December 2004, San Antonio, Texas, USA [poster 409].
11. J.N. Ingle K.M. Rowland V.J. Suman et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: A phase II trial of the North Central Cancer Treatment Group Breast Cancer Res Treat 88 Suppl. 1 2004 S38 [abstr 409]
12. L. Mauriac J.E. Pippen J. Quaresma Albano S.Z. Gertler C.K. Osborne Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials Eur J Cancer 39 2003 1228-1233
13. N.L. Fernie J.M. Zekri R.C.F. Leonard R.E. Coleman D.A. Cameron Exemestane in metastatic breast cancer: Effective therapy after 3rd generation aromatase inhibitor failure Breast Cancer Res Treat 82 Suppl. 1 2003 S104 [abstr 435]
14. A. Howell J.F.R. Robertson P. Abram et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial J Clin Oncol 22 2004 1605-1613